Sponsored Links

Coffee associated with lower liver cancer risk

Wed Jun 6, 2007 8:50am EDT
 
[-] Text [+]

NEW YORK (Reuters Health) - Drinking coffee appears to lower the risk of developing liver cancer, according to findings published in the medical journal Gastroenterology.

"Data on potential beneficial effects of coffee on liver function and liver diseases have accrued over the last two decades," Drs. Susanna C. Larsson and Alicja Wolk, from the Karolinska Institute, Stockholm, write. Several studies have found an inverse relationship between coffee consumption and liver enzymes levels that indicate a risk of chronic liver disease and cirrhosis.

The researchers therefore conducted a large review, or "meta-analysis," of published epidemiological studies to look at the association between coffee consumption and the risk of liver cancer. The meta-analysis included 11 studies involving 2,260 liver cancer patients and 239,146 individuals without liver cancer who served as a comparison group.

An inverse association between coffee consumption and liver cancer risk was observed in all of the studies, and this association was statistically significant in six studies.

For every 2 cups of coffee per day, the investigators observed a 43-percent reduced risk of liver cancer.

"A protective effect of coffee consumption on liver cancer is biologically plausible," Larsson and Wolk point out. "Coffee contains large amounts of antioxidants, such as chlorogenic acids," which combat oxidative stress and inhibit the formation of carcinogens. Furthermore, experimental animal studies have specifically shown that coffee and chlorogenic acids have an inhibitory effect on liver cancer.

SOURCE: Gastroenterology, May 2007.

 

Editor's Choice

A selection of our best photos from the past 24 hours.  Slideshow 

Most Popular on Reuters

  • Articles
  • Video
A customer shops for medicine at a Portland, Oregon drugstore July 31, 2005. REUTERS/Richard Clement RC/YH
Blame game slows growth of personalized medicine

Expectation has been building for a decade that an era of personalized medicine will transform the global drugs business, but the reality is a slow start and an angry blame game between scientists, marketers and regulators.  Full Article